On Tuesday, DealerTrack Technologies Inc (NASDAQ:TRAK)’s shares declined -0.24% to $62.16.
Dealertrack Technologies ( TRAK) received two Bronze Stevie® Awards at the recent 13th Annual American Business Awards in Chicago. Dealertrack received an award for its Digital Retailing Solution in the “Innovation of the Year - Business Products Industries” category, and the company’s Dealer.com Seamless Websites were honored in the “Automotive & Transport Equipment & Transportation” websites category.
The American Business Awards are the nation’s premier business awards program recognizing a broad spectrum of American business professionals and organizations – from non-profits, emerging start-ups, major public companies and government agencies to corner-office executives, corporate communicators, support staff and customer service teams. A second Stevie Awards ceremony will be held in San Francisco on September 11, 2015, honoring additional winners in the new product and technology-related categories. Dealertrack’s eMenu for iPad is a finalist in the “Integrated Mobile Experience” category, which is planned to be declared at the San Francisco ceremony.
Dealertrack Technologies, Inc. provides Web-based software solutions and services to the automotive retail industry in the United States and Canada. It offers digital marketing solutions, which provide Websites, digital advertising, and other digital marketing offerings to assist dealers in achieving higher lead conversion rates that assist to optimize various shoppers to their Websites; dealer administration solutions, which provide dealer administration system featuring tools and real-time data access; and F&I solutions that allow dealers to streamline the in-store and online sales, in addition to financing processes.
Stoneridge, Inc. (NYSE:SRI)’s shares gained 0.44% to $11.30.
Stoneridge Inc., (SRI), a leading supplier of driver information systems to the global, commercial vehicle, truck, bus and automotive markets, and Orlaco Products BV, a leading supplier of vehicle camera solutions, have executed a planned alliance agreement to develop, manufacture and sell electronic mirror replacement systems. The unique mirror replacement system integrates Orlaco camera technology and Stoneridge driver information technology (display, electronics and system integration) into an innovative, industry-leading product that enhances safety and improves fuel economy.
Under the agreement, the two companies will design, develop and produce mirror replacement systems targeted initially at the commercial vehicle and off-road transportation markets. Stoneridge will act as the Tier 1 supplier and be responsible for the overall system and vehicle interior products, and Orlaco will be responsible for the vehicle exterior products. These systems will comply with ISO 16505 Camera Monitor Systems.
Stoneridge, Inc. designs and manufactures electrical and electronic components, modules, and systems for the automotive, commercial vehicle, motorcycle, off-highway, and agricultural vehicle markets primarily in North America, South America, and Europe. It operates through three segments: Control Devices, Electronics, and PST.
At the end of Tuesday’s trade, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)‘s shares surged 2.11% to $2.90.
OncoGenex Pharmaceuticals, Inc. (OGXI) declared that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is ongoing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis.
Two interim analyses were originally planned to evaluate whether to stop the trial for futility. OncoGenex filed an amendment with the U.S. Food and Drug Administration amending the statistical design and analysis plan that comprised of a more rigorous and expedient evaluation of the potential survival benefit associated with custirsen in NSCLC. Based on current enrollment, initial ENSPIRIT results could be accessible in the second half of 2016.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates comprise Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, in addition to in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers.
Peregrine Pharmaceuticals (NASDAQ:PPHM), ended its Tuesday’s trading session with -3.79% loss, and closed at $1.27.
Peregrine Pharmaceuticals, Inc. (PPHM) a biopharmaceutical company focused on developing novel investigational products that assist harness the body’s own immune system to fight cancer, declared financial results for the fourth quarter and the fiscal year (FY) 2015 ended April 30, 2015 and offered an update on its advancing clinical pipeline and other corporate developments.
Highlights Since January 31, 2015:
“During the fourth quarter, Peregrine achieved multiple milestones spanning all areas of the business. Most importantly, we remain on plan to complete patient enrollment in the SUNRISE Phase III trial in NSCLC by the end of calendar year 2015, while also planning for the initiation of two new trials designed to further expand our breast and non-small cell lung cancer clinical programs,” said Steven W. King, president and chief executive officer of Peregrine. “Our promising new partnership with Memorial Sloan Kettering Cancer Center, together with the considerable amount of pre-clinical and clinical data that has been generated, serves to further validate bavituximab and its potential to enhance the effects of chemotherapy, in addition to immune checkpoint targeting treatments. Recently, we are more confident than ever in bavituximab and we are plannedally expanding our clinical programs to capture the value that we believe exists in new therapeutic combinations and indications. Specifically, we are expanding our NSCLC clinical program to comprise a planned Phase II study combining bavituximab with Opdivo®, an FDA-approved PD-1 inhibitor, while also initiating a planned Phase II/III clinical trial in breast cancer combining bavituximab with chemotherapy. In addition to our drug development efforts, Avid achieved record revenue during this fiscal year 2015 and is on track to grow its revenue in FY 2016 based on the growing backlog of services and the near-term launch of the new manufacturing facility. We look forward to providing updates on our bavituximab clinical program, data from presently enrolling clinical trials and collaborative development efforts in the coming months.”
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer together with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
